SCHEMBL9944185

SCHEMBL9944185

CCCOc1c(Cl)cc(C(=O)Nc2ccc(C(C)=O)cc2)cc1Cl

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 3/20 0.58
MAPT P10636 7/20 0.55
NPSR1 Q6W5P4 1/20 0.55
TAS1R3 Q7RTX0 1/20 0.53
TAS1R1 Q7RTX1 1/20 0.53
TAS1R2 Q8TE23 1/20 0.53
RAB9A P51151 5/20 0.52
KMT2A Q03164 4/20 0.52
NPC1 O15118 3/20 0.52
MEN1 O00255 3/20 0.52
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 2/20 0.49
TSHR P16473 1/20 0.49
MCL1 Q07820 1/20 0.49
HSD17B10 Q99714 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.48
SIRT2 Q8IXJ6 1/20 0.48
SIRT1 Q96EB6 1/20 0.48
TP53 P04637 2/20 0.47
HPGD P15428 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1457725 0.90 PLAU (0.62) PLAUMAPTNPSR1TAS1R3TAS1R1
SCHEMBL9944170 0.90 KMT2A (0.64) PLAUMAPTNPSR1TAS1R3TAS1R1
SCHEMBL9944194 0.82 KMT2A (0.56) PLAUMAPTNPSR1TAS1R3TAS1R1
SCHEMBL9944178 0.81 PLAU (0.58) PLAUMAPTTAS1R3TAS1R1TAS1R2
SCHEMBL9944167 0.81 TAS1R3 (0.50) PLAUMAPTTAS1R3TAS1R1TAS1R2
SCHEMBL9944219 0.81 TAS1R3 (0.55) MAPTNPSR1TAS1R3TAS1R1TAS1R2
SCHEMBL9944177 0.80 TAS1R3 (0.57) PLAUMAPTTAS1R3TAS1R1TAS1R2
SCHEMBL9944168 0.80 SCD (0.55) PLAUMAPTTAS1R3TAS1R1TAS1R2
SCHEMBL1458773 0.79 MEN1 (0.75) PLAUMAPTTAS1R3TAS1R1TAS1R2
SCHEMBL9944171 0.79 TAS1R3 (0.56) PLAUMAPTTAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG PLAU 4014/4885MAPT 150/4885NPSR1 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.